Plural Chalcogens Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding Patents (Class 514/425)
-
Publication number: 20120149753Abstract: Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of A. camphorata in a solid culture. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds and pharmaceutical compositions including the compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: February 16, 2012Publication date: June 14, 2012Applicant: Well Shine Biotechnology Development Co,, Ltd.Inventors: Yueh-Hsiung Kuo, Bi-Fong Lin
-
Publication number: 20120134977Abstract: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.Type: ApplicationFiled: June 1, 2010Publication date: May 31, 2012Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yoram Shechter, Matityahu Fridkin
-
Patent number: 8188145Abstract: Natural and synthetic compounds having a lactone structure methods for alleviation of pain, especially pain associated with disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer. Initial studies have shown that patients can be taken off of morphine when the preferred alpha-methylene-gamma-butyrolactone is administered in a dosage of between 60 and 120 mg/day intramuscularly.Type: GrantFiled: April 18, 2005Date of Patent: May 29, 2012Assignee: Magnachem International Laboratories, Inc.Inventors: Federico M. Gomez, C. Federico Gomez Garcia-Godoy
-
Patent number: 8148420Abstract: Methods of stimulating immune response or treating an inflammatory disorder with one of a number of the compounds disclosed herein or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 30, 2010Date of Patent: April 3, 2012Assignee: Well Shine Biotechnology Development Co., Ltd.Inventors: Yueh-Hsiung Kuo, Bi-Fong Lin
-
Patent number: 8138182Abstract: The present invention relates to a diketohydrazine derivative of formula (I) and a pharmaceutically acceptable salt thereof (the symbols in the formula have the same meaning as described in the specification). The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory activity against elastase and it is also useful for the treatment of COPD (chronic obstacle pulmonary diseases).Type: GrantFiled: September 24, 2009Date of Patent: March 20, 2012Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Akira Hatayama, Hiroshi Tsuruta, Yasuo Ochi, Haruo Imawaka, Kazuyuki Ohmoto
-
Publication number: 20120058193Abstract: An injectable smart gel and a method for fabricating the same are disclosed. A basic structural stabilizer/polymeric electrolyte and a diluting solution are added to a modified chitosan to regulate the chitosan solution to have a pH value closing to that of the human body and form a flowable chitosan sol. The flowable chitosan sols formed thereby are respectively converted into inflowable chitosan gels via increasing the temperature thereof to the human body temperature, and via adding calcium ion or regulating the chitosan sol into an acidic solution. The injectable smart gel fabricated thereby is injectable and able to function as a carrier of magnetism-sensitive medicine-containing nanocapsules. The medicine can be released to the injectable smart gel with an external non-contact force, such as a magnetic field, an electric field or an ultrasonic wave, for long-acting and multi-stage medicine delivery. The present invention is very useful in biomedical engineering.Type: ApplicationFiled: April 4, 2011Publication date: March 8, 2012Inventors: Dean-Mo LIU, Meng-Hsuan Hsiao, Li Jie Lin
-
Publication number: 20120046337Abstract: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing ?- and ?-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human ?-hexosaminidase, a new target for development of osteoarthritis therapeutics.Type: ApplicationFiled: February 24, 2011Publication date: February 23, 2012Inventors: Pi-Hui Liang, Yi-Ling Lin, Chi-Huey Wong
-
3-BIPHENYL-SUBSTITUTED-3-SUBSTITUTED-4-KETOLACTAM AND KETOLACTONE AND THEIR UTILIZATION AS PESTICIDE
Publication number: 20120028804Abstract: The present invention relates to novel 3-biphenyl-substituted, 3-substituted 4-ketolactams and -lactones of the formula (I) in which A, B, Q, G, W, X, Y and Z are as defined in the disclosure, to processes for their preparation, and to their use as pesticides and/or microbicides and/or herbicides.Type: ApplicationFiled: October 23, 2007Publication date: February 2, 2012Inventors: Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Mark Wilhelm Drewes, Christoph Erdelen, Angelika Lubos-Erdelen, Dieter Feucht, Udo Reckmann, Karl-Heinz Kuck, Ulrike Wachendorff-Neumann -
Publication number: 20120016001Abstract: The present invention provides methods and pharmaceutical compositions for treating ocular disorders associated with elevated intraocular pressure, such as glaucoma, by administering antiepileptic or anti-convulsant compounds of the succinimide family, in particular compounds of formula I and/or II as defined herein.Type: ApplicationFiled: September 6, 2011Publication date: January 19, 2012Inventor: MORDECHAI SHARIR
-
Patent number: 8093386Abstract: There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R1, R2, n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors of zinc metalloproteinases.Type: GrantFiled: July 25, 2007Date of Patent: January 10, 2012Assignee: Bracco Imaging S.p.AInventors: Armando Rossello, Elisabetta Orlandini, Aldo Balsamo, Laura Panelli, Elisa Nuti
-
Publication number: 20120004251Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.Type: ApplicationFiled: March 30, 2011Publication date: January 5, 2012Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma LimitedInventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
-
Publication number: 20110305632Abstract: The present invention relates to a method of making asymmetrical bis(thiosemicarbazones), compounds useful as synthetic intermediates in the method, new bis(thiosemicarbazones) that can be readily accessed by use of the method and methods of treatment and imaging utilising some of the new bis(thiosemicarbazones).Type: ApplicationFiled: December 11, 2009Publication date: December 15, 2011Applicant: THE UNIVERSITY OF MELBOURNEInventors: Paul Stephen Donnelly, Brett Michael Paterson
-
Publication number: 20110301217Abstract: The application relates to an immoalditol compound for selectively inhibiting glycosidases, a prodrug thereof and a pharmaceutical composition comprising the compound or the prodrug The application also relates to the use of the immoalditol compound for treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc Such diseases and disorders include neurodegenerative diseases, tauopathy, cancers, and cardiac disordersType: ApplicationFiled: September 16, 2009Publication date: December 8, 2011Inventors: David Jaro Vocadlo, Ernest Mceachern
-
Publication number: 20110294783Abstract: The present invention concerns boosting the activity of crop protection materials comprising inhibitors of fatty acid biosynthesis (for example phenyl-substituted cyclic ketoenols) through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium salts and/or phosphonium salts and penetrants, the corresponding materials, processes for preparing them, and their use in crop protection.Type: ApplicationFiled: August 10, 2011Publication date: December 1, 2011Applicant: BAYER CROPSCIENCE AGInventors: Reiner FISCHER, Stefan LEHR, Peter MARCZOK, Udo Reckmann, Christian Arnold, Waltraud Hempel, Erich SANWALD, Rolf Pontzen
-
Publication number: 20110288076Abstract: This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. In particularly, this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonist and methods for using the S1P1 receptor antagonist, such as in the treatment of cancer, and processes for making the S1P1 receptor antagonists.Type: ApplicationFiled: October 16, 2009Publication date: November 24, 2011Applicant: EXELIXIS, INC.Inventors: Mohamed Abdulkader Ibrahim, Joon Won Jeong, Henry William Beecroft Johnson, Patrick Kearney, James W. Leahy, Gary L. Lewis, Robin Tammie Noguchi, John M. Nuss
-
Publication number: 20110281921Abstract: Novel agents exhibiting anti-biofilm formation activity while being non-cytotoxic are provided, as well as methods of using the same, either per se or conjugated to a polymer, for preventing and/or reducing the formation of microbial biofilms and/or for disrupting microbial biofilms. The novel agents described herein include thiazolidine-2,4-diones (TZDs), pyrrolidine-2,5-diones (PYDs), imidazolidine-2,4-diones or oxazolidine-2,4-diones, substituted by an alkyl having 7-20 carbon atoms in its backbone chain.Type: ApplicationFiled: November 19, 2009Publication date: November 17, 2011Applicants: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Morris Srebnik, Itzhack Polacheck, Doron Steinberg, Adel Jabbour, Edward Sionov
-
Publication number: 20110280813Abstract: The invention is related to various methods for inhibiting or reducing biofilm formation, treating a biofilm production-related disorder, preventing biofilm formation, and screening for neuraminidase inhibitors.Type: ApplicationFiled: November 13, 2009Publication date: November 17, 2011Inventors: Alice Prince, Liang Tong
-
Publication number: 20110281879Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: ApplicationFiled: January 12, 2011Publication date: November 17, 2011Applicant: ViroBay, Inc.Inventor: Craig Mossman
-
Publication number: 20110268822Abstract: Compounds having the general formula (I): wherein X is S, Se or NH, and stereoisomers thereof, and de-O-sulfonated analogues of all of the foregoing, but excluding naturally occurring kotalanol and de-O-sulfonated kotalanol, and methods for synthesizing same. The compounds are useful as glycosidase inhibitors, and may be used in the treatment of diabetes. The synthetic compounds may also be used as standards in the calibration or grading of natural or herbal remedies produced from natural sources of glycosidase inhibitors such as kotalanol.Type: ApplicationFiled: March 25, 2009Publication date: November 3, 2011Applicant: SIMON FRASER UNIVERSITYInventors: Brian Mario Pinto, Jayakanthan Kumarasamy, Ravindranath Nasi, Sankar Mohan
-
Publication number: 20110263519Abstract: The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.Type: ApplicationFiled: July 5, 2011Publication date: October 27, 2011Applicant: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINEInventors: Philip A. Beachy, James K. Chen, Anssi Jussi Nikolai Taipale
-
Publication number: 20110263540Abstract: Small-molecule inhibitors of a protein synthesis inhibiting toxin, e.g., ricin, abrin, Shiga, and Shiga-like toxins, as well as methods of using the inhibitors are provided. Further provided are methods of identifying small-molecule inhibitors of a protein synthesis inhibiting toxin.Type: ApplicationFiled: July 24, 2009Publication date: October 27, 2011Inventors: Yuan-Ping Pang, Nilgun Ereken Tumer, Charles B. Millard
-
Publication number: 20110256150Abstract: The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.Type: ApplicationFiled: October 22, 2009Publication date: October 20, 2011Applicant: Genentech, Inc.Inventors: Ryan Watts, Mark Chen, Joseph Wesley Lewcock, Christine Pozniak, Arundhati Sengupta-Ghosh
-
Publication number: 20110257242Abstract: The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating dopamine neurotransmission and extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications.Type: ApplicationFiled: November 24, 2009Publication date: October 20, 2011Applicant: NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGEInventors: Clas Sonesson, Lars Swanson, Fredrik Pettersson
-
Publication number: 20110245218Abstract: The present invention relates to the use of new and known maleimide salts for controlling phytopathogenic fungi, and also to methods for controlling phytopathogenic fungi in crop protection, in the household and hygiene sectors and in materials protection, and also to crop protection compositions comprising these maleimide salts.Type: ApplicationFiled: March 4, 2011Publication date: October 6, 2011Applicant: Bayer CropScience AGInventors: Thomas SEITZ, Thomas Himmler, Jürgen Benting, Ulrike Wachendorff-Neumann
-
Publication number: 20110230346Abstract: The invention relates to novel compounds of the formula (I) in which W, X, Y, Z, and CKE have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides and/or fungicides. Moreover, the invention relates to selectively herbicidal compositions comprising, firstly, the biphenyl-substituted cyclic ketoenols and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to the boosting of the action of crop protection compositions comprising in particular biphenyl-substituted cyclic ketoenols through the addition of ammonium or phosphium salts and optionally penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as insecticides and/or nematicides and/or acaricides and/or fungicides and/or for preventing unwanted plant growth.Type: ApplicationFiled: February 10, 2011Publication date: September 22, 2011Applicant: Bayer CropScience AGInventors: Reiner FISCHER, Stefan Lehr, Isolde Häuser-Hahn, Christopher Hugh Rosinger, Chieko Ueno, Arnd Voerste, Elmar Gatzweiler, Ines Heinemann, Ulrich Görgens
-
Patent number: 8013009Abstract: The invention relates to the use of plasma membrane calcium ATPase (PMCA) inhibitors for inhibiting sperm mobility to achieve a contraceptive effect. The invention further relates to contraceptive agents comprising one or more PMCA inhibitors.Type: GrantFiled: July 1, 2004Date of Patent: September 6, 2011Inventor: Ludwig Neyses
-
Patent number: 8008341Abstract: The present invention relates to benzsulfonamide derivatives of formula I and methods of use thereof. The benzsulfonamide derivatives of the present invention are efficient modulators of the JNK pathway. In particular the benzsulfonamide derivatives of the present invention are selective inhibitors of JNK 2 and 3.Type: GrantFiled: June 19, 2008Date of Patent: August 30, 2011Assignee: Merck Serono SAInventors: Serge Halazy, Dennis Church, Stephen J. Arkinstall, Marco Biamonte, Montserrat Camps, Jean-Pierre Gotteland, Thomas Rueckle
-
Publication number: 20110201666Abstract: The present invention relates to compounds from mycelium of Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) infection.Type: ApplicationFiled: April 26, 2011Publication date: August 18, 2011Applicant: SIMPSON BIOTECH CO., LTD.Inventors: CHIA-CHIN SHEU, MASAO HATTORI
-
Publication number: 20110195929Abstract: Described are various compounds and methods for the treatment of flaviviral infections. In particular, alkaloids and imino sugars in arabinose and/or lyxose stereochemical configuration with antiflaviviral activity are described.Type: ApplicationFiled: August 4, 2009Publication date: August 11, 2011Applicant: SUMMIT CORPORATION PLCInventors: Olivier De Moor, Graeme Horne, Penny Jane Middleton, Frank Schroer, Stephen Paul Wren, Maria Ines Passos Eleuterio, Renate Van Well, Colin Richard Dorgan, Francis Xavier Wilson, Robert Nash, Richard Storer, Graham Michael Wynne, Alan Geoffrey Roach, Akane Kawamura, Jonathon Mark Tinsley
-
Publication number: 20110183849Abstract: The present invention relates to novel C2-phenyl-substituted cyclic ketoenols of the formula (I) in which W, X, Y, Z and CKE are as defined in the description, to processes for their preparation and to their use as pesticides and herbicides.Type: ApplicationFiled: March 24, 2011Publication date: July 28, 2011Applicant: Bayer AktiengesellschaftInventors: Michael Ruther, Hermann Hagemann, Udo Schneider, Markus Dollinger, Peter Dahmen, Ulrike Wachendorff-Neumann, Reiner Fischer, Alan Graff, Thomas Bretschneider, Christoph Erdelen, Mark Wilhelm Drewes, Dieter Feucht, Folker Lieb
-
Publication number: 20110172171Abstract: The present invention relates to taurine or taurine-like substances for the prevention of brain oedema, particularly brain intramyelinic oedema and more particularly brain intramyelinic oedema induced by an anti-convulsive drug such as vigabatrin. The invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention of brain oedema.Type: ApplicationFiled: September 4, 2009Publication date: July 14, 2011Inventors: Serge Picaud, José-Alain Sahel, Firas Jammoul
-
Publication number: 20110172240Abstract: The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative.Type: ApplicationFiled: January 7, 2011Publication date: July 14, 2011Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
-
Publication number: 20110143943Abstract: The present invention relates to novel C2-phenyl-substituted cyclic ketoenols of the formula (I) in which W, X, Y, Z and CKE are as defined in the description, to processes for their preparation and to their use as pesticides and herbicides.Type: ApplicationFiled: February 17, 2011Publication date: June 16, 2011Applicant: Bayer AktiengesellschaftInventors: Michael RUTHER, Hermann Hagemann, Udo Schneider, Markus Dollinger, Peter Dahmen, Ulrike Wachendorff-Neumann, Reiner Fischer, Alan Graff, Thomas Bretschneider, Christoph Erdelen, Mark Wilhelm Drewes, Dieter Feucht, Folker Lieb
-
Publication number: 20110130352Abstract: The present invention relates to an effective fraction of alkaloids and the effective fraction is prepared from mulberry twig and its active ingredients are a composition of alkaloids. Determined by HPLC, the percentage of the total alkaloids are 50% or more by weight in the effective fraction and the percentage of the compound 1-deoxynojirimycin is 30% or more by weight in the total alkaloids. The effective fraction of the invention is prepared as the following steps: the mulberry twig is extracted by solvents, and the extract is precipitated by alcohol precipitation or flocculation to remove the impurities, and then concentrated, purified by resin chromatography. The present invention also relates to a pharmaceutical composition containing the said effective fraction of alkaloids and to the use of the effective fraction of alkaloids according to claim 1-4 in preparing hypoglycemic agents.Type: ApplicationFiled: August 22, 2007Publication date: June 2, 2011Applicant: Institute of Materia Medica Chinese Academy of Medical SciencesInventors: Yuling Liu, Zhufang Shen, Zhen Chen, Renyun Wang, Xuejun Xia, Yueteng Chen, Quan Liu, Sujuan Sun, Mingzhi Xie
-
Publication number: 20110118174Abstract: A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and/or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed.Type: ApplicationFiled: January 24, 2011Publication date: May 19, 2011Inventor: JinJun Zhang
-
Publication number: 20110104294Abstract: The present invention discloses a magnetic nanocomposite for inhibiting/treating cancer and a method for fabricating the same. The magnetic nanocomposite comprises a core formed of a plurality of magnetic nanoparticles made of ferric ferrous oxide (Fe3O4); a shell made of a carboxy-functionalized polyaniline; and an anti-tumor medicine bound to the external surface of the shell. The method of the present invention fast fabricates the magnetic nanocomposite in a simple way. The medicine of the present invention has a longer half life and a better thermal stability. The present invention disperses the water-insoluble medicine in water uniformly to decrease the biological rejection. Moreover, the magnetic nanocomposite of the present invention is guided to the nidus by an external magnetic field to increase the local concentration of the medicine and provide an effective chemotherapy. Therefore, the present invention has competitive advantage over the conventional BCNU.Type: ApplicationFiled: May 4, 2010Publication date: May 5, 2011Inventors: Mu-Yi Hua, Hung-Wei Yang, Rung-Ywan Tsai, Kuo-Chen Wei, Pin-Yuan Chen, Chiung-Yin Huang
-
Publication number: 20110098336Abstract: A compound represented by the formula (I) according to claim 1 or a salt thereof has a superior androgen receptor modulating action.Type: ApplicationFiled: August 6, 2008Publication date: April 28, 2011Applicant: Takeda Pharmaceutical Company LimitedInventor: Atsushi Hasuoka
-
Publication number: 20110098276Abstract: The invention relates to oxycarbamoyl compounds of Formula I: The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.Type: ApplicationFiled: June 11, 2009Publication date: April 28, 2011Inventor: Hidenori Mikamiyama
-
Patent number: 7932285Abstract: Compounds isolated from the fruiting body of A. camphorata in a solid culture or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: November 21, 2008Date of Patent: April 26, 2011Assignee: Well Shine Biotechnology Development Co., Ltd.Inventors: Yueh-Hsiung Kuo, Bi-Fong Lin
-
Publication number: 20110092368Abstract: The present invention relates to novel 2,4,6-phenyl-substituted cyclic ketoenols of the formula (I) in which W, X, Y and CKE have the meanings given in the disclosure, to a plurality of processes for their preparation and to their use as pesticides and/or herbicides. The invention further relates to selectively herbicidal compositions containing 2,4,6-phenyl-substituted cyclic ketoenols and a compound which improves crop plant tolerance.Type: ApplicationFiled: December 17, 2010Publication date: April 21, 2011Inventors: Reiner Fischer, Klaus Kunz, Stefan Lehr, Michael Ruther, Udo Schneider, Markus Dollinger, Mark Wilhelm Drewes, Dieter Feucht, Jörg Konze, Ulrike Wachendorff-Neumann, Guido Bojack, Thomas Auler, Martin Jeffrey Hills, Thomas Bretschneider, Olga Malsam, Christoph Erdelen, Angelika Lubos-Erdelen, Alfred Angermann, Hein Kehne, Christopher Hugh Rosinger
-
3-biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide
Patent number: 7928037Abstract: The present invention relates to novel 3-biphenyl-substituted, 3-substituted 4-keto-lactams and -lactones of the formula (I) in which A, B, Q, G, W, X, Y and Z are as defined in the disclosure, to processes for their preparation, and to their use as pesticides and/or microbicides and/or herbicides.Type: GrantFiled: October 23, 2007Date of Patent: April 19, 2011Assignee: Bayer CropScience AGInventors: Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Mark Wilhelm Drewes, Christoph Erdelen, Angelika Lubos-Erdelen, legal representative, Dieter Feucht, Udo Reckmann, Karl-Heinz Kuck, Ulrike Wachendorff-Neumann -
Publication number: 20110086761Abstract: The present invention relates to fungicidal compositions and their use for controlling oomycete pathogen induced disease or diseases in one or more plants.Type: ApplicationFiled: October 13, 2010Publication date: April 14, 2011Applicant: DOW AGROSCIENCES LLCInventors: Norman R. Pearson, Lei Liu, Robert J. Ehr, John M. Atkinson
-
Publication number: 20110077282Abstract: Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of A. camphorata in a solid culture. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds and pharmaceutical compositions including the compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: November 30, 2010Publication date: March 31, 2011Applicant: Well Shine Biotechnology Development Co., Ltd.Inventors: Yueh-Hsiung Kuo, Bi-Fong Lin
-
Patent number: 7915304Abstract: The invention discloses the use of a compound of formula (I), wherein R1, R2, R3, and R4 each independently represents: hydrogen; halo; hydroxy; (C1-C6) alkyl optionally substituted by hydroxy or (C1-C4) alkoxy; (C1-C6) haloalkyl; (C1-C6) alkoxy; and (C1-C6) haloalkoxy; for the preparation of a medicament for the prevention and/or treatment of diseases resulting from opening of the MPTP which are characterized by degenerative tissue damages, in particular, diabetes and diabetic complications, neurological diseases and stroke, heart infarction, inherited dystrophies and hepatitis, more particularly, diabetic vascular diseases, such as diabetic retinopathy, and neurodegenerative disorders, such as multiple sclerosis. Further objects are a group of selected individual compounds of formula (I) for use as medicaments and a further group of selected individual compounds of formula (I) as novel compounds.Type: GrantFiled: September 21, 2007Date of Patent: March 29, 2011Assignee: Congenia S.r.l.Inventors: PierGiuseppe Pellicci, Marco Giorgio, Saverio Minucci, Paolo Bernardi, Gilles Pain, Stephen Martin Courtney, Christopher John Yarnold, Joachim Kraemer
-
Patent number: 7910618Abstract: The present invention provides an albumin-binding compound essentially of the following elements: a spacer group, a water-soluble bridging group, a fatty acid chain and an acidic group characterised in that the acidic group is attached to the distal end of the fatty acid chain. The invention also provides an albumin-binding compound to which one or more biologically active moieties are attached.Type: GrantFiled: May 25, 2005Date of Patent: March 22, 2011Assignee: UCB Pharma S.A.Inventors: Michael Anthony Eaton, Timothy John Norman, John Robert Porter
-
Publication number: 20110059148Abstract: Nanodevice and method for in vivo monitoring and release of drugs are provided. The disclosed nanodevice is characterized in having a drug-loaded nanosphere that is capable of releasing the encapsulated drugs upon magnetically stimulation. The nanodevice may also be used as a contrast agent for in vivo imaging and monitoring the concentration and distribution of the released drugs and/or active compounds injected separately into a target site of a subject.Type: ApplicationFiled: September 7, 2009Publication date: March 10, 2011Applicant: NATIONAL CHIAO TUNG UNIVERSITYInventors: San-Yuan Chen, Wei-Chen Huang, Dean-Mo Liu
-
Publication number: 20110009261Abstract: A compound of the formula (I) where, for example, W, X and Y are each CH; R1 and R6 together with the adjacent nitrogen forms a 3 to 10-membered saturated ring, wherein the ring may contain, in addition to the nitrogen and carbon ring members, 1, 2 or 3 heteroatoms and/or heteroatom groups as ring members, independently of one another, selected from the group consisting of sulfur, CO, SO, SO2 and N—R7 and/or the ring may carry 1, 2 or 3 radicals, independently of one another, each selected, for example, from the group consisting of halogen, cyano, nitro, amino, and C1-C6-alkyl. R2 is, for example, halogen, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy or C1-C6-alkoxy-C1-C6-alkoxy, and R7 is for example, R10C(?O), C1-C6 alkyl or C1-C6-haloalkyl; and/or salts thereof; and their use as pesticidal agents.Type: ApplicationFiled: March 2, 2009Publication date: January 13, 2011Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Peter Maienfisch, Ottmar Hueter, Peter Renold, Werner Zambach, Thomas Pitterna
-
Publication number: 20100317690Abstract: Described are various compounds and methods for the treatment of disorders arising from aberrant protein folding, including in particular lysosomal storage diseases. In particular, polyhydroxylated alkaloids and imino sugars which are pharmacoperones of an enzyme and which do not bind to a catalytic site of said enzyme are described.Type: ApplicationFiled: November 20, 2008Publication date: December 16, 2010Inventors: Akane Kawamura, Alan Geoffrey Roach, Francis Xavier Wilson, Jonathon Mark Tinsley, Robert Nash, Richard Storer
-
Patent number: 7850955Abstract: Gelling agents which contain a specific N-acylamino acid monoamide monoalkyl ester have a melting temperature of about 100° C., are capable of solidifying a wide variety of oily base materials including silicones, and do not cause “sweating” while retaining a practical level of gel strength. When applied to skin, the resulting gels have a good feeling, good spreadability, and good fittability to skin.Type: GrantFiled: July 3, 2008Date of Patent: December 14, 2010Assignee: Ajinomoto Co., Inc.Inventors: Keitaro Saito, Takanori Sugimoto, Tatsuya Hattori
-
Patent number: 7834051Abstract: The present invention relates to pharmaceutical agents which are agents for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; the pharmaceutical agents frailty suppressants, muscle strength enhancers, muscle increasing agents, cachexia suppressants, body weight decrease suppressants, agents for the prophylaxis or treatment of prostate hypertrophy, amyotrophy or muscle loss caused by a disease or an agent for reducing the prostate weight.Type: GrantFiled: August 6, 2008Date of Patent: November 16, 2010Assignee: Takeda Pharmaceutical Company LimitedInventor: Atsushi Hasuoka